Effects of felodipine combined with puerarin on ACE2-Ang (1-7)-Mas axis in renovascular hypertensive rat

Regulatory Peptides

Volumn 184, Issue , 2013, Pages 54-61

  Bai, Song ^a   Huang, Zheng Gui ^a   Chen, Li ^a   Wang, Jiang Tao ^a   Ding, Bo Ping ^a  

^a WANNAN MEDICAL COLLEGE   (China)

Author keywords

ACE2 Ang (1 7) Mas axis; Blood pressure; Felodipine+puerarin; Goldblatt rat; Heart rate; Renal interstitial fibrosis

Indexed keywords

ANGIOTENSIN II; ANGIOTENSIN[1-7][7 DEXTRO ALANINE]; CAPTOPRIL; FELODIPINE; MESSENGER RNA; PUERARIN; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME REGULATION; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT; RENAL PROTECTION; RENOVASCULAR HYPERTENSION; TREATMENT DURATION; TREATMENT RESPONSE;

ANGIOTENSIN I; ANIMALS; DRUG THERAPY, COMBINATION; FELODIPINE; HYPERTENSION, RENOVASCULAR; ISOFLAVONES; KIDNEY; PEPTIDE FRAGMENTS; PEPTIDYL-DIPEPTIDASE A; PROTO-ONCOGENE PROTEINS; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, G-PROTEIN-COUPLED; VASODILATOR AGENTS;

ANIMALIA; RATTUS;

EID: 84876303353     PISSN: 01670115     EISSN: 18731686     Source Type: Journal    
DOI: 10.1016/j.regpep.2013.03.005     Document Type: Article

References (30)

1. Herlitz H., Aurell M., Björck S., Granérus G. Renal effects of felodipine in hypertensive patients with reduced renal function. Drugs 1985, 29(Suppl. 2):192-197.
2. Huang Z.G., Cheng H.Z., Zhang N.B., Ding B.P. Effects of puerarin on level of angiotensin II in left cardiac ventricle and its protective effect on left ventricular hypertrophy. Pract Pharm Clin Remedies 2010, 13:161-163. [Chinese with English abstract].
3. Grobe J.L., Mecca A.P., Mao H., Katovich M.J. Chronic angiotensin-(1-7) prevents cardiac fibrosis in DOCA-salt model of hypertension. Am J Physiol Heart Circ Physiol 2006, 290(6):2417-2423.
4. Warner G.M., Cheng J., Knudsen B.E., Gray C.E., Deibel A., Juskewitch J.E., et al. Genetic deficiency of Smad3 protects the kidneys from atrophy and interstitial fibrosis in 2K1C hypertension. Am J Physiol Renal Physiol 2012, 302(11):1455-1464.
5. Benter I.F., Yousif M.H., Al-Saleh F.M., Raghupathy R., Chappell M.C., Diz D.I. Angiotensin-(1-7) blockade attenuates captopril- or hydralazine-induced cardiovascular protection in spontaneously hypertensive rats treated with NG-nitro-l-arginine methyl ester. J Cardiovasc Pharmacol 2011, 57(5):559-567.
6. Uhal B.D., Li X., Xue A., Gao X., Abdul-Hafez A. Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. Am J Physiol Lung Cell Mol Physiol 2011, 301(3):269-274.
7. Bürgelová M., Vanourková Z., Thumová M., Dvorák P., Opocenský M., Kramer H.J., et al. Impairment of the angiotensin-converting enzyme 2-angiotensin-(1-7)-Mas axis contributes to the acceleration of two-kidney, one-clip Goldblatt hypertension. J Hypertens 2009, 27(10):1988-2000.
8. Ferrario C.M., Varagic J. The ANG-(1-7)/ACE2/mas axis in the regulation of nephron function. Am J Physiol Renal Physiol 2010, 298(6):1297-1305.
9. Giani J.F., Muñoz M.C., Pons R.A., Cao G., Toblli J.E., Turyn D., et al. Angiotensin-(1-7) reduces proteinuria and diminishes structural damage in renal tissue of stroke-prone spontaneously hypertensive rats. Am J Physiol Renal Physiol 2011, 300(1):272-282.
10. Zhong J., Guo D., Chen C.B., Wang W., Schuster M., Loibner H., et al. Prevention of angiotensin II-mediated renal oxidative stress, inflammation, and fibrosis by angiotensin-converting enzyme 2. Hypertension 2011, 57(2):314-322.
11. Gersch M.S., Mu W., Cirillo P., Reungjui S., Zhang L., Roncal C., et al. Fructose, but not dextrose, accelerates the progression of chronic kidney disease. Am J Physiol Renal Physiol 2007, 293(4):1256-1261.
12. Kaplan N.M. Combination therapy for hypertension. Nat Rev Cardiol 2009, 6(4):270-271.
13. Jamerson K.A., Nwose O., Jean-Louis L., Schofield L., Purkayastha D., Baron M. Initial angiotensin-converting enzyme inhibitor/calcium channel blocker combination therapy achieves superior blood pressure control compared with calcium channel blocker monotherapy in patients with stage 2 hypertension. Am J Hypertens 2004, 17(6):495-501.
14. Valli G., Giardina E.G. Benefits, adverse effects and drug interactions of herbal therapies with cardiovascular effects. J Am Coll Cardiol 2002, 39(7):1083-1095.
15. Normile D. Asian medicine. The new face of traditional Chinese medicine. Science 2003, 299(5604):188-190.
16. Efferth T., Li P.C., Konkimalla V.S., Kaina B. From traditional Chinese medicine to rational cancer therapy. Trends Mol Med 2007, 13(8):353-361.
17. Wang L., Zhou B.Z., Liu P., Song J.H., Liang Y., Yan X.J., et al. Dissection of mechanisms of Chinese medicinal formula Realgar-Indigo naturalis as an effective treatment for promyelocytic leukemia. Proc Natl Acad Sci U S A 2008, 105(12):4826-4831.
18. Geng Y.J. The nitrate-nitrite-nitric oxide pathway in traditional herbal medicine for heart disease. Nitrite and nitrate in human health and disease 2011, 247-261. Humana Press, New York. N.S. Bryan, J. Loscalzo (Eds.).
19. Chen S.L., Liu X.Y., Xu W.M., Mei W.Y., Chen X.L. Clinical study of western medicine combined with Chinese medicine based on syndrome differentiation in the patients with polarized hypertension. Chin J Integr Med 2012, 18(10):746-751.
20. Liu C.M., Ma J.Q., Sun Y.Z. Puerarin protects rat kidney from lead-induced apoptosis by modulating the PI3K/Akt/eNOS pathway. Toxicol Appl Pharmacol 2012, 258(3):330-342.
21. Sun X.H., Ding J.P., Li H., Pan N., Gan L., Yang X.L., et al. Activation of large-conductance calcium-activated potassium channels by puerarin: the underlying mechanism of puerarin-mediated vasodilation. J Pharmacol Exp Ther 2007, 323(1):391-397.
22. Lu X.R., Gao E., Xu L.Z., Li H.Z., Kang B., Chen W.N., et al. Puerarin beta-adrenergic receptor blocking effect. Chin Med J 1987, 100(1):25-28.
23. Rüster C., Wolf G. Angiotensin II as a morphogenic cytokine stimulating renal fibrogenesis. J Am Soc Nephrol 2011, 22(7):1189-1199.
24. Iekushi K., Taniyama Y., Kusunoki H., Azuma J., Sanada F., Okayama K., et al. Hepatocyte growth factor attenuates transforming growth factor-β-angiotensin II crosstalk through inhibition of the PTEN/Akt pathway. Hypertension 2011, 58(2):190-196.
25. Liu Z., Huang X.R., Chen H.Y., Penninger J.M., Lan H.Y. Loss of angiotensin-converting enzyme 2 enhances TGF-β/Smad-mediated renal fibrosis and NF-κB-driven renal inflammation in a mouse model of obstructive nephropathy. Lab Invest 2012, 92(5):650-661.
26. Prieto M.C., González-Villalobos R.A., Botros F.T., Martin V.L., Pagán J., Satou R., et al. Reciprocal changes in renal ACE/ANG II and ACE2/ANG 1-7 are associated with enhanced collecting duct renin in Goldblatt hypertensive rats. Am J Physiol Renal Physiol 2011, 300(3):749-755.
27. Gallagher P.E., Chappell M.C., Ferrario C.M., Tallant E.A. Distinct roles for ANG II and ANG-(1-7) in the regulation of angiotensin-converting enzyme 2 in rat astrocytes. Am J Physiol Cell Physiol 2006, 290(2):420-426.
28. Jiang T., Gao L., Shi J.Q., Lu J., Wang Y., Zhang Y.D. Angiotensin-(1-7) modulates renin-angiotensin system associated with reducing oxidative stress and attenuating neuronal apoptosis in the brain of hypertensive rats. Pharmacol Res 2013, 67(1):84-93.
29. Abbas A., Gorelik G., Carbini L.A., Scicli A.G. Angiotensin-(1-7) induces bradykinin-mediated hypotensive responses in anesthetized rats. Hypertension 1997, 30(2 Pt 1):217-221.
30. Pörsti I., Bara A.T., Busse R., Hecker M. Release of nitric oxide by angiotensin-(1-7) from porcine coronary endothelium: implications for a novel angiotensin receptor. Br J Pharmacol 1994, 111(3):652-654.